Latest news and press releases about Kiniksa Pharmaceuticals International, plc (KNSA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Price
| Price | $77.62 |
| Market Cap | $5.9B |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| P/E Ratio | 70.23 |
| Price / Book | 8.91 |
| EV / EBITDA | 49.60 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 13.65% |
| Return on Invested Capital | 9.71% |
| Return on Assets | 9.00% |
| Gross Margin | 54.49% |
| Operating Margin | 11.92% |
| Net Margin | 9.59% |
Related companies: ADPT · APLS · CDTX · CPRX · FOLD · IDYA · MLYS
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of KNSA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks